Advertisement

AIDS and Behavior

, Volume 21, Issue 5, pp 1256–1267 | Cite as

PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists

  • Andrew E. PetrollEmail author
  • Jennifer L. Walsh
  • Jill L. Owczarzak
  • Timothy L. McAuliffe
  • Laura M. Bogart
  • Jeffrey A. Kelly
Original Paper

Abstract

HIV pre-exposure prophylaxis (PrEP) was FDA approved in 2012, but uptake remains low. To characterize what would facilitate health care providers’ increased PrEP prescribing, we conducted a 10-city, online survey of 525 primary care providers (PCPs) and HIV providers (HIVPs) to assess awareness, knowledge, and experience with prescribing PrEP; and, comfort with and barriers to PrEP-related activities. Fewer PCPs than HIVPs had heard of PrEP (76 vs 98%), felt familiar with prescribing PrEP (28 vs. 76%), or had prescribed it (17 vs. 64%). PCPs were less comfortable than HIVPs with PrEP-related activities such as discussing sexual activities (75 vs. 94%), testing for acute HIV (83 vs. 98%), or delivering a new HIV diagnosis (80 vs. 95%). PCPs most frequently identified limited knowledge about PrEP and concerns about insurance coverage as prescribing barriers. PCPs and HIVPs differ in needs that will facilitate their PrEP prescribing. Efforts to increase PrEP uptake will require interventions to increase the knowledge, comfort, and skills of providers to prescribe PrEP.

Keywords

HIV prevention HIV pre-exposure prophylaxis Health care providers Barriers 

Resumen

Profilaxis pre-exposición por VIH (PrEP) fue aprobado por la FDA en 2012, pero su utilización ha sido lento. Para caracterizar lo que facilataría un aumento de la prescripción de profilaxis pre-exposición entre los proveedores de salud, se realizó una encuesta en línea con 525 proveedores de atención primaria (PAP) y los proveedores de VIH (PVIH) en diez ciudades, para evaluar la conciencia, conocimiento y la experiencia con la prescripción de profilaxis pre-exposición; y comodidad con y barreras a las actividades relacionadas con la prescripción de PrEP. Menos PAPs que PVIHs habían oído hablar de profilaxis pre-exposición (76 vs 98%), se sentía familiarizado con prescripción de profilaxis pre-exposición (28 vs. 76%), o habían prescrito (17 vs. 64%). Los PAPs eran menos cómodo que PVIHs con actividades relacionadas con la PrEP como hablar sobre las actividades sexuales (75 vs. 94%), las pruebas de VIH aguda (83 vs. 98%), o la entrega de un nuevo diagnóstico de VIH (80 vs. 95%). Los PAPs frecuentemente identificaron un conocimiento limitado sobre PrEP y preocupaciones acerca de la cobertura de seguro como barreras de prescripción. PAPs y PVIHs difieren en las necesidades que van a facilitar su prescripción de PrEP. Los esfuerzos para aumentar la absorción de la PrEP requerirán intervenciones para aumentar el conocimiento, la comodidad, y las habilidades de los proveedores para prescribir PrEP.

Palabras Claves

Prevención del VIH Profilaxis pre-exposición al VIH Proveedores de servicios de salud Barreras 

Notes

Funding

This work was supported by Gilead Sciences, Inc. and the National Institute of Mental Health at the National Institutes of Health [Grant Numbers 5P30MH052776, K01-MH099956].

Compliance with Ethical Standards

Conflict of interest

A.P. receives research support from Gilead Sciences, Inc. J.W., J.O., T.M., L.B., and J.K. report no conflict of interest.

Research Involving Human Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

This study was reviewed by the Institutional Review Board of the Medical College of Wisconsin. It met the Board’s definition of “minimal risk” and a waiver of informed consent was granted.

References

  1. 1.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMedGoogle Scholar
  2. 2.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Molina J, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on Retroviruses and Opportunistic Infections. Seattle, 2015 [Abstract 23LB].Google Scholar
  5. 5.
    McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015;387(10013):53–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mera R, McCallister S, Palmer B, et al. Truvada for HIV pre-exposure prophylaxis (PrEP) utilization in the United States (2013–2015). 21st International AIDS Conference. Durban, 2016 [Abstract TUAX0105LB].Google Scholar
  10. 10.
    Laufer F, O’Connell DA, Feldman I. Increased Medicaid Prescriptions for Preexposure Prophylaxis Against HIV infection—New York, 2012–2015. MMWR Morb Mortal Wkly Rep. 2015;64(Early Release):1–6.Google Scholar
  11. 11.
    Smith DK, Mendoza MCB, Stryker JE, Rose CE. PrEP awareness and attitudes in a national survey of primary care clinicians in the United States, 2009–2015. PLoS ONE. 2016;11(6):e0156592.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Grant R, Hecht J, Raymond H. Scale-up of pre-exposure prophylaxis in San Francisco to impact HIV incidence. Conference on Retroviruses and Opportunistic Infections. Seattle, 2015 [Abstract 25].Google Scholar
  13. 13.
    Smith DK, Van Handel M, Wolitski RJ, Stryker JE, Hall HI, Prejean J. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1291–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18(9):1712–21.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K, et al. Knowledge is power! increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19(5):802–10.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS. 2013;27(10):553–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Tripathi A, Whiteside YO, Duffus WA. Perceptions and attitudes about preexposure prophylaxis among seronegative partners and the potential of sexual disinhibition. South Med J. 2013;106(10):558–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Desai M, Gafos M, Dolling D, McCormack S, Nardone A. Healthcare providers’ knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. HIV Med. 2015;15:28.Google Scholar
  19. 19.
    Adams LM, Balderson B, Packett BJ, Brown K, Catz SL. Providers’ perspectives on prescribing pre-exposure prophlaxis (PrEP) for HIV prevention. HIV Specialist. 2015;7(1):18–25.Google Scholar
  20. 20.
    Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, Steward WT, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE. 2012;7(7):e40603.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58(5):704–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Seidman D, Carlson K, Weber S, Witt J, Kelly PJ. United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey. Contracept. 2016;93(5):463–9.CrossRefGoogle Scholar
  23. 23.
    Adams LM, Balderson BH. HIV providers’ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. AIDS Care. 2016; doi: 10.1080/09540121.2016.1153595.PubMedCentralGoogle Scholar
  24. 24.
    Sachdev DD, Stojanovski K, Liu AY, Buchbinder SP, Macalino GE. Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs. Clin Infect Dis. 2014;58(12):1786–7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mimiaga MJ, White JM, Krakower DS, Biello KB, Mayer KH. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care. 2014;26(6):684–93.CrossRefPubMedGoogle Scholar
  26. 26.
    White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012;26(7):395–405.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Sharma M, Wilton J, Senn H, Fowler S, Tan DH. Preparing for PrEP: perceptions and readiness of canadian physicians for the implementation of HIV pre-exposure prophylaxis. PLoS ONE. 2014;9(8):e105283.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Krakower DS, Oldenburg CE, Mitty JA, Wilson IB, Kurth AE, Maloney KM, et al. Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS ONE. 2015;10(7):e0132398.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Smith, D, Mendoza, M, Rose, C. PrEP Awareness and attitudes in a nationally representative survey of primary care clinicians in the United States, 2009–2013. US National HIV Prevention Conference. 2015, Atlanta [Abstract 1686].Google Scholar
  30. 30.
    Desai M, Gafos M, Dolling D, McCormack S, Nardone A. PROUD study. Healthcare providers’ knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. HIV Med. 2016;17(2):133–42.CrossRefPubMedGoogle Scholar
  31. 31.
    Centers for Disease Control and Prevention (CDC). Preexposure prophylaxis for the prevention of HIV infection in the United States–2014: A clinical practice guideline. Atlanta: CDC; 2014.Google Scholar
  32. 32.
    Centers for Disease Control and Prevention (CDC). HIV Surveillance report, 2014. November, 2015. Report No.: 26.Google Scholar
  33. 33.
    Calabrese SK, Magnus M, Mayer KH, et al. Putting PrEP into practice: lessons learned from early-adopting US providers’ firsthand experiences providing HIV pre-exposure prophylaxis and associated care. PLoS ONE. 2016;11(6):e0157324.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68:337–44.CrossRefPubMedGoogle Scholar
  35. 35.
    Fonner VA, Dalglish SL, Kennedy CE, et al. Effecitveness and safety of oral HIV pre-exposure prophylaxis for all populations. AIDS. 2016;30:1973–83.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Andrew E. Petroll
    • 1
    Email author
  • Jennifer L. Walsh
    • 1
  • Jill L. Owczarzak
    • 2
  • Timothy L. McAuliffe
    • 1
  • Laura M. Bogart
    • 3
  • Jeffrey A. Kelly
    • 1
  1. 1.Center for AIDS Intervention Research (CAIR)Medical College of WisconsinMilwaukeeUSA
  2. 2.Johns Hopkins UniversityBaltimoreUSA
  3. 3.RAND CorporationSanta MonicaUSA

Personalised recommendations